Sara Bringhen

10.5k total citations
112 papers, 2.3k citations indexed

About

Sara Bringhen is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Sara Bringhen has authored 112 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Hematology, 68 papers in Molecular Biology and 67 papers in Oncology. Recurrent topics in Sara Bringhen's work include Multiple Myeloma Research and Treatments (107 papers), Protein Degradation and Inhibitors (48 papers) and Peptidase Inhibition and Analysis (42 papers). Sara Bringhen is often cited by papers focused on Multiple Myeloma Research and Treatments (107 papers), Protein Degradation and Inhibitors (48 papers) and Peptidase Inhibition and Analysis (42 papers). Sara Bringhen collaborates with scholars based in Italy, United States and France. Sara Bringhen's co-authors include Mario Boccadoro, Francesca Gay, Antonio Palumbo, Patrizia Falco, Pellegrino Musto, Giovannino Ciccone, Antonio Palumbo, Benedetto Bruno, Paola Omedè and Antonietta Falcone and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Sara Bringhen

107 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sara Bringhen Italy 21 2.0k 1.6k 1.3k 174 122 112 2.3k
Alessandra Larocca Italy 20 1.1k 0.5× 895 0.6× 719 0.6× 159 0.9× 105 0.9× 101 1.5k
Arleigh McCurdy Canada 14 1.4k 0.7× 1.2k 0.8× 918 0.7× 249 1.4× 109 0.9× 92 1.8k
Qaiser Bashir United States 22 1.4k 0.7× 762 0.5× 745 0.6× 273 1.6× 219 1.8× 182 2.0k
Donna Weber United States 23 1.8k 0.9× 1.5k 0.9× 1.2k 0.9× 378 2.2× 110 0.9× 79 2.7k
Adam Waxman United States 12 534 0.3× 422 0.3× 470 0.4× 108 0.6× 150 1.2× 32 935
Alan Barge United Kingdom 14 664 0.3× 411 0.3× 819 0.7× 183 1.1× 117 1.0× 21 1.5k
Roger Chen United States 13 1.2k 0.6× 1.1k 0.7× 767 0.6× 402 2.3× 496 4.1× 26 2.3k
Agnieszka Wierzbowska Poland 22 1.5k 0.7× 1.1k 0.7× 483 0.4× 461 2.6× 227 1.9× 108 2.3k
Daryl Sonnichsen United States 23 360 0.2× 483 0.3× 881 0.7× 337 1.9× 28 0.2× 45 1.6k
Kelly J. Norsworthy United States 13 409 0.2× 449 0.3× 319 0.3× 139 0.8× 137 1.1× 42 1.0k

Countries citing papers authored by Sara Bringhen

Since Specialization
Citations

This map shows the geographic impact of Sara Bringhen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Bringhen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Bringhen more than expected).

Fields of papers citing papers by Sara Bringhen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Bringhen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Bringhen. The network helps show where Sara Bringhen may publish in the future.

Co-authorship network of co-authors of Sara Bringhen

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Bringhen. A scholar is included among the top collaborators of Sara Bringhen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Bringhen. Sara Bringhen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vallelonga, Fabrizio, Dario Leone, Francesca Gay, et al.. (2025). Validation of the HFA-ICOS Score for Carfilzomib-Induced Cardiotoxicity in Multiple Myeloma: A Real-Life Perspective Study. Cancers. 17(14). 2353–2353.
2.
Martino, Massimo, Barbara Gamberi, Elisabetta Antonioli, et al.. (2024). Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?. Expert Review of Hematology. 17(7). 375–390. 3 indexed citations
3.
Vallelonga, Fabrizio, Dario Leone, Sara Bringhen, et al.. (2024). Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment. Cancers. 16(17). 3081–3081.
4.
Fazio, Francesca, Maria Teresa Petrucci, Laura Corvatta, et al.. (2024). Belantamab mafodotin in triple‐refractory multiple myeloma patients: A retro‐prospective observational study in Italy. SHILAP Revista de lepidopterología. 5(3). 485–493. 1 indexed citations
5.
6.
Leone, Dario, Fabrizio Vallelonga, Sara Bringhen, et al.. (2023). Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience. Cancers. 15(4). 1149–1149. 2 indexed citations
7.
Larocca, Alessandra, et al.. (2023). New Strategies for the Treatment of Older Myeloma Patients. Cancers. 15(10). 2693–2693. 8 indexed citations
8.
Bringhen, Sara, Luděk Pour, Reuben Benjamin, et al.. (2023). Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study. Clinical Lymphoma Myeloma & Leukemia. 23(7). 491–504. 2 indexed citations
9.
Oliva, Stefania, Lorenzo De Paoli, Marina Ruggeri, et al.. (2021). A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma. Annals of Hematology. 100(2). 437–443. 8 indexed citations
10.
Vallelonga, Fabrizio, Michele Covella, Dario Leone, et al.. (2021). Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction. Cancers. 13(7). 1631–1631. 11 indexed citations
11.
D’Agostino, Mattia, Gian Maria Zaccaria, Bachisio Ziccheddu, et al.. (2020). Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing. Clinical Cancer Research. 26(18). 4832–4841. 38 indexed citations
12.
Dimopoulos, Meletios Α., Ivan Špıčka, Hang Quach, et al.. (2020). Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. Journal of Clinical Oncology. 38(34). 4030–4041. 53 indexed citations
13.
Bringhen, Sara, Roberto Mina, Anna Maria Cafro, et al.. (2018). Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. Leukemia. 32(8). 1803–1807. 34 indexed citations
14.
15.
Bringhen, Sara, Nicola Giuliani, A.M. Liberati, et al.. (2016). CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (KCYD) IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS: INITIAL RESULTS OF A PHASE 1 STUDY. Haematologica. 101(1). 520–520. 1 indexed citations
16.
Donato, Francesca, Francesca Gay, Sara Bringhen, Rossella Troia, & Antonio Palumbo. (2014). Monoclonal antibodies currently in Phase II and III trials for multiple myeloma. Expert Opinion on Biological Therapy. 14(8). 1127–1144. 10 indexed citations
17.
Larocca, Alessandra, Vittorio Montefusco, Sara Bringhen, et al.. (2013). Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood. 122(16). 2799–2806. 66 indexed citations
18.
19.
Palumbo, Antonio, Sara Bringhen, Anna Marina Liberati, et al.. (2008). Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 112(8). 3107–3114. 250 indexed citations
20.
Bringhen, Sara, Alessandra Bertola, Federica Cavallo, et al.. (2003). TWO DOSE-INTENIVE MELPHALAN REGIMENS (100 MG/M2 VERSUS 200 MG/M2) IN MULTIPLE MYELOMA PATIENTS. Haematologica. 88. 17–18. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessandra Larocca Breakdown of academic impact, for papers by Arleigh McCurdy Breakdown of academic impact, for papers by Qaiser Bashir Breakdown of academic impact, for papers by Donna Weber Breakdown of academic impact, for papers by Adam Waxman Breakdown of academic impact, for papers by Alan Barge Breakdown of academic impact, for papers by Roger Chen Breakdown of academic impact, for papers by Agnieszka Wierzbowska Breakdown of academic impact, for papers by Daryl Sonnichsen Breakdown of academic impact, for papers by Kelly J. Norsworthy
Rankless by CCL
2026